Actively Recruiting
Ilaris NIS in Korea
Led by Novartis Pharmaceuticals · Updated on 2025-12-30
25
Participants Needed
1
Research Sites
183 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome / Mevalonate kinase deficiency (HIDS/MKD) or Systemic juvenile idiopathic arthritis (sJIA).
CONDITIONS
Official Title
Ilaris NIS in Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent or assent from the patient or their legal representative/parent for participation
- Age 2 years and older, including pediatric patients under 19 and adults 19 years and older with hereditary periodic fever syndromes (CAPS, crFMF, TRAPS, HIDS/MKD) or sJIA
- Patient agrees to be treated with Ilaris or has already started treatment following approved label information
You will not qualify if you...
- Patients receiving Ilaris for autoimmune diseases other than CAPS, crFMF, TRAPS, HIDS/MKD, or sJIA
- Patients currently participating in an interventional clinical trial that affects routine clinical treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Novartis Investigative Site
Seoul, South Korea, 03722
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here